Evidence map›Paper›PMID 34172091›Full record

ArticleMolecular neurodegeneration2021

A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy.

Laura Gutierrez-Quiceno, Eric B Dammer, Ashlyn Grace Johnson, James A Webster, Rhythm Shah, Duc Duong, Luming Yin, Nicholas T Seyfried, Victor E Alvarez, Thor D Stein and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Laura Gutierrez-Quiceno *Center for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
Eric B Dammer *Center for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
Ashlyn Grace JohnsonCenter for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
James A WebsterCenter for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
Rhythm ShahCenter for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
Duc DuongCenter for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
Luming YinCenter for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
Nicholas T SeyfriedCenter for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA.
Victor E AlvarezBoston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, 72 East Concord St, Boston, MA, 02118, USA.
Thor D SteinBoston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, 72 East Concord St, Boston, MA, 02118, USA.
Ann C McKeeBoston University Alzheimer's Disease and CTE Center, Boston University School of Medicine, 72 East Concord St, Boston, MA, 02118, USA.
Chadwick M HalesCenter for Neurodegenerative Disease, Emory University School of Medicine, 615 Michael Street, Office 505H, Atlanta, GA, 30322, USA. cmhales@emory.edu.ORCID 0000-0002-8757-7325
Emory University · USBoston University · US

Funding

Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0M
The Emory Alzheimer's Disease CenterP50AG025688 · NIA · EMORY UNIVERSITY · PI WALKER, LARY C · 2005 to 2019
$25.7M
Discovery of Novel Proteomic Targets in Alzheimer's DiseaseU01AG046161 · NIA · EMORY UNIVERSITY · PI BENNETT, DAVID ALAN, GESCHWIND, DANIEL H · 2014 to 2018
$8.4M
CTE and Posttraumatic Neurodegeneration: Neuropathology and Ex Vivo ImagingU01NS086659 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MCKEE, ANN C. · 2014 to 2017
$6.1M
Tau Pathology in CTE vs. Alzheimer's Disease: Microvasculopathy and NeuroinflammationRF1AG057902 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MCKEE, ANN C. · 2017 to 2017
$4.1M
Investigating RNA splicing factor aggregations in Alzheimer's disease and CTEK08NS087121 · NINDS · EMORY UNIVERSITY · PI HALES, CHADWICK M · 2014 to 2018
$858k
CSRD VA I01 CX001038NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG066511NIA NIH HHS P50 AG025688NIA NIH HHS RF1 AG057902NIA NIH HHS U01 AG046161NINDS NIH HHS K08 NS087121NINDS NIH HHS U01 NS086659
6 · The paper itself

Abstract

backgroundThere is an association between repetitive head injury (RHI) and a pathologic diagnosis of chronic traumatic encephalopathy (CTE) characterized by the aggregation of proteins including tau. The underlying molecular events that cause these abnormal protein accumulations remain unclear. Here, we hypothesized that identifying the human brain proteome from serial CTE stages (CTE I-IV) would provide critical new insights into CTE pathogenesis. Brain samples from frontotemporal lobar degeneration due to microtubule associated protein tau (FTLD-MAPT) mutations were also included as a distinct tauopathy phenotype for comparison.

methodsIsobaric tandem mass tagged labeling and mass spectrometry (TMT-MS) followed by integrated differential and co-expression analysis (i.e., weighted gene co-expression network analysis (WGCNA)) was used to define modules of highly correlated proteins associated with clinical and pathological phenotypes in control (n = 23), CTE (n = 43), and FTLD-MAPT (n = 12) post-mortem cortical tissues. We also compared these findings to network analysis of AD brain.

resultsWe identified over 6000 unique proteins across all four CTE stages which sorted into 28 WGCNA modules. Consistent with Alzheimer's disease, specific modules demonstrated reduced neuronal protein levels, suggesting a neurodegeneration phenotype, while other modules were increased, including proteins associated with inflammation and glial cell proliferation. Notably, unique CTE-specific modules demonstrated prominent enrichment of immunoglobulins, including IGHM and IGLL5, and extracellular matrix (ECM) proteins as well as progressive protein changes with increasing CTE pathologic stage. Finally, aggregate cell subtype (i.e., neurons, microglia, astrocytes) protein abundance levels in CTE cases were similar in expression to AD, but at intermediate levels between controls and the more exaggerated phenotype of FTLD-MAPT, especially in astrocytes.

conclusionsOverall, we identified thousands of protein changes in CTE postmortem brain and demonstrated that CTE has a pattern of neurodegeneration in neuronal-synaptic and inflammation modules similar to AD. We also identified unique CTE progressive changes, including the enrichment of immunoglobulins and ECM proteins even in early CTE stages. Early and sustained changes in astrocyte modules were also observed. Overall, the prominent overlap with FTLD-MAPT cases confirmed that CTE is on the tauopathy continuum and identified CTE stage specific molecular phenotypes that provide novel insights into disease pathogenesis.

Indexed as

BrainChronic Traumatic EncephalopathyHumansPhenotypeProteomicsAstrocyteChronic traumatic encephalopathy (CTE)Frontotemporal dementia (FTD)ImmunoglobulinProteomicsTandem mass tagged (TMT)Weighted gene co-expression network analysis (WGCNA)

Identifiers

PMID34172091
PMCPMC8235576
OpenAlexW3173778575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.